StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen NEUPOGEN (filgrastim by Quarter

NEUPOGEN (filgrastim — Neutropenia, legacy standalone disclosure) — U.S. product sales ($M) ($M)

QuarterlyAnnual

Amgen NEUPOGEN (filgrastim: $22M in Q4 2022, up 46.7% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2022
22
Period ended Dec 31, 2022
Change on a year earlier
+46.7%
15 in Q4 2021
History
24 quarters
Since Q1 2017
Sources
22
Documents cited below

Where the Q4 2022 figure comes from

“|| NEUPOGEN ® | 22 | 12 | 34 | 31 | 10%”

Source: Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNEUPOGEN (filgrastim — Neutropenia, legacy standalone disclosure) — U.S. product sales ($M) ($M)Year on yearSource
Q4 2022Dec 31, 202222+46.7%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 202221-34.4%Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022Jun 30, 202221-41.7%Form 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗
Q1 2022Mar 31, 202223+27.8%Form 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗
Q4 2021Dec 31, 202115-44.4%Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
Q3 2021Sep 30, 202132-27.3%Form 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021Jun 30, 202136+28.6%Form 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗
Q1 2021Mar 31, 202118-60.0%Form 8-K (amgn-2021331xq1ex991.htm, filed 2021-04-27) ↗
Q4 2020Dec 31, 202027-34.1%Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗
Q3 2020Sep 30, 202044+37.5%Form 8-K (amgn-2020930xq3ex991.htm, filed 2020-10-28) ↗
Q2 2020Jun 30, 202028-49.1%Form 8-K (amgn-2020630xq1ex991.htm, filed 2020-07-28) ↗
Q1 2020Mar 31, 202045-10.0%Form 8-K (amgn-2020331xq1ex991.htm, filed 2020-04-30) ↗
Q4 2019Dec 31, 201941-4.7%Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗
Q3 2019Sep 30, 201932-38.5%Form 8-K (amgn-2019930xq3exhibit.htm, filed 2019-10-29) ↗
Q2 2019Jun 30, 201955-12.7%Form 8-K (amgn-2019630xq2exhibit991f.htm, filed 2019-07-30) ↗
Q1 2019Mar 31, 201950-23.1%Form 8-K (amgn-2019331xq1exhibit991f.htm, filed 2019-04-30) ↗

Cite this data

StockData. (2026). Amgen NEUPOGEN (filgrastim ($M), quarterly Q1 2017–Q4 2022 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-neupogen-us

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.